13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
69 檔
15.0%
As reported in its official Q1 2025 Form 13F filing, Deep Track Capital, LP's tracked investment portfolio stood at $6.9B with 69 total positions.
In Q1 2025, Deep Track Capital, LP displayed an active expansion posture, initiating 16 new positions and adding to 25 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 8.54% | — | — | |
| 2 | GH | Guardant Health Inc | Stock-Healthcare | 7.51% | +2.37% | -15.20% | |
| 3 | DVAX | Dynavax Technologies CORP | Stock-Other | 7.47% | — | — | |
| 4 | IMVT | Immunovant Inc | Stock-Other | 5.26% | +0.56% | +58.33% | |
| 5 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.70% | — | +200.00% | |
| 6 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 4.46% | +0.15% | +136.01% | |
| 7 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.21% | — | +115.45% | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.00% | -0.61% | +22.95% | |
| 9 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.54% | -2.98% | EXIT | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.39% | +0.09% | +11.36% | |
| 11 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.13% | -1.02% | EXIT | |
| 12 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.47% | -0.76% | — | |
| 13 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.35% | +0.51% | +18.96% | |
| 14 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.30% | +0.33% | +46.43% | |
| 15 | ETNBGBP | 89bio Inc | Stock-Other | 2.19% | — | +43.81% | |
| 16 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.12% | +1.12% | +83.33% | |
| 17 | GERN | Geron CORP | Stock-Other | 1.97% | -0.77% | EXIT | |
| 18 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.86% | — | — | |
| 19 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.58% | — | +106.58% | |
| 20 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.52% | -0.75% | EXIT | |
| 21 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.38% | — | — | |
| 22 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.36% | -0.81% | +171.75% | |
| 23 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.18% | +0.92% | +29.86% | |
| 24 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.17% | -0.08% | — | |
| 25 | AMGN | Amgen Inc | Stock-Healthcare | 1.14% | — | — | |
| 26 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.09% | — | +491.25% | |
| 27 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.00% | — | +97.07% | |
| 28 | ✓ | Stock-Other | 0.96% | — | — | ||
| 29 | PCVX | Vaxcyte Inc | Stock-Other | 0.92% | -0.44% | — | |
| 30 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.90% | — | +25.53% | |
| 31 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.84% | +0.45% | — | |
| 32 | CMPS | Compass Pathways PLC | Stock-Other | 0.82% | +1.40% | — | |
| 33 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.80% | — | — | |
| 34 | ABVX | Abivax Sa-adr | Stock-Other | 0.72% | — | — | |
| 35 | MBX | Mbx Biosciences Inc | Stock-Other | 0.72% | +0.05% | — | |
| 36 | GHRS | GH Research PLC | Stock-Other | 0.71% | +1.30% | NEW | |
| 37 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.68% | -0.11% | — | |
| 38 | ✓ | Engene Holdings Inc | Stock-Other | 0.66% | -0.49% | EXIT | |
| 39 | INSM | Insmed Inc | Stock-Healthcare | 0.63% | — | — | |
| 40 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.60% | — | -5.09% | |
| 41 | SG7 | Sage Therapeutics Inc | Stock-Other | 0.52% | — | — | |
| 42 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.50% | -0.92% | EXIT | |
| 43 | KRRO | Korro Bio Inc | Stock-Other | 0.49% | — | — | |
| 44 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.48% | +1.04% | +92.63% | |
| 45 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.47% | — | -11.24% | |
| 46 | UPB | Upstream Bio Inc | Stock-Other | 0.46% | — | +129.96% | |
| 47 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.42% | +0.27% | NEW | |
| 48 | SEPN | Septerna Inc | Stock-Other | 0.36% | — | — | |
| 49 | NVAX | Novavax Inc | Stock-Healthcare | 0.32% | — | -24.09% | |
| 50 | HELP | Cybin Inc | Stock-Other | 0.31% | -0.10% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | +3.3% | +200.00% | Add |
| 2 | AKRO | Akero Therapeutics Inc | +2.7% | +115.45% | Add |
| 3 | TARS | Tarsus Pharmaceuticals Inc | +2.5% | NEW | New buy |
| 4 | ITCIEUR | Intra-cellular Therapies Inc | +2.3% | — | Unchanged |
| 5 | BBIO | Bridgebio Pharma Inc | +2.3% | +241.81% | Add |
| 6 | IONS | Ionis Pharmaceuticals Inc | +1.9% | +136.01% | Add |
| 7 | SRPT | Sarepta Therapeutics Inc | +1.9% | NEW | New buy |
| 8 | GERN | Geron CORP | +1.4% | +851.72% | Add |
| 9 | DNTH | Dianthus Therapeutics Inc | +1.4% | NEW | New buy |
| 10 | MAZE | Maze Therapeutics Inc | +1.2% | NEW | New buy |
| 11 | AMGN | Amgen Inc | +1.1% | NEW | New buy |
| 12 | ✓ | +1% | NEW | New buy | |
| 13 | PCVX | Vaxcyte Inc | +0.9% | NEW | New buy |
| 14 | XENE | Xenon Pharmaceuticals Inc | +0.8% | +491.25% | Add |
| 15 | CMPS | Compass Pathways PLC | +0.8% | NEW | New buy |
| 16 | TECX | Tectonic Therapeutic Inc | +0.8% | NEW | New buy |
| 17 | IMCR | Immunocore Holdings Plc-adr | +0.8% | +171.75% | Add |
| 18 | GHRS | GH Research PLC | +0.7% | NEW | New buy |
| 19 | INSM | Insmed Inc | +0.6% | NEW | New buy |
| 20 | RARE | Ultragenyx Pharmaceutical In | +0.6% | +106.58% | Add |
| 21 | SG7 | Sage Therapeutics Inc | +0.5% | NEW | New buy |
| 22 | ETNBGBP | 89bio Inc | +0.3% | +43.81% | Add |
| 23 | EWTX | Edgewise Therapeutics Inc | +0.3% | +97.07% | Add |
| 24 | BEAM | Beam Therapeutics Inc | +0.2% | NEW | New buy |
| 25 | GH | Guardant Health Inc | +0.2% | -15.20% | Trim |
| 26 | ANIP | Ani Pharmaceuticals Inc | +0.2% | +7.85% | Add |
| 27 | RAPP | Rapport Therapeutics Inc | +0.2% | NEW | New buy |
| 28 | ✓ | Ikena Oncology Inc | +0.1% | NEW | New buy |
| 29 | NGNE | Neurogene Inc | 0% | NEW | New buy |
| 30 | NRIX | Nurix Therapeutics Inc | 0% | +83.33% | Add |
| 31 | IVVD | Invivyd Inc | 0% | -9.05% | Trim |
| 32 | RGLS | Regulus Therapeutics Inc | 0% | — | Unchanged |
| 33 | AVTX | Avalo Therapeutics Inc | 0% | -0.82% | Trim |
| 34 | CLYM | Climb Bio Inc | 0% | — | Unchanged |
| 35 | FLNA | Filana Therapeutics Inc | 0% | EXIT | Sold out |
| 36 | INO | Inovio Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 37 | ORKA | Oruka Therapeutics Inc | -0.1% | +92.63% | Add |
| 38 | NKTREUR | Nektar Therapeutics | -0.1% | EXIT | Sold out |
| 39 | SYRE | Spyre Therapeutics Inc | -0.1% | — | Unchanged |
| 40 | OKUR | Onkure Therapeutics Inc-a | -0.1% | — | Unchanged |
| 41 | ✓ | Rapt Therapeutics Inc | -0.1% | — | Unchanged |
| 42 | FDMT | 4d Molecular Therapeutics In | -0.1% | EXIT | Sold out |
| 43 | CNTX | Context Therapeutics Inc | -0.1% | — | Unchanged |
| 44 | UPB | Upstream Bio Inc | -0.2% | +129.96% | Add |
| 45 | ✓ | Zura Bio LTD | -0.2% | — | Unchanged |
| 46 | HELP | Cybin Inc | -0.2% | — | Unchanged |
| 47 | LKFT | Lakefront Biotherapeutic-adr | -0.2% | -5.09% | Trim |
| 48 | ALLKGUSD | Allakos Inc | -0.2% | +26.79% | Add |
| 49 | ALGS | Aligos Therapeutics Inc | -0.2% | +81.93% | Add |
| 50 | XNCR | Xencor Inc | -0.2% | +9.89% | Add |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 69 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ITCIEUR, GH, DVAX) accounted for 15.0% of total reported equity market value during Q1 2025.
Top New Position Initiated
TARS
市值: $76.2M
Top Position Liquidated / Trimmed
SWTXUSD
前期市值: $125.0M
During Q1 2025, Deep Track Capital, LP's top holdings by market value included ITCIEUR (8.5%)、GH (7.5%)、DVAX (7.5%). The largest single position, ITCIEUR, represented 8.5% of total portfolio value.
In Q1 2025, Deep Track Capital, LP made 58 total portfolio adjustments, initiating 16 new buys, adding to 25 positions, trimming 8 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.